应用生理学精准医学优化试验设计:体外二氧化碳清除治疗急性呼吸窘迫综合征
在ARDS治疗临床试验中,个体患者反应差异大导致平均治疗效应被稀释,推高样本量需求并增加试验成本与难度。本文以体外二氧化碳清除(ECCO2R)用于超保护性通气为例,应用精准医学范式,用基础生理学概念证明死腔和静态顺应性决定ECCO2R对驱动压和机械功率的影响,该框架或可预测个体治疗反应。在既有ARDS队列中模拟显示,若仅纳入ECCO2R可使驱动压降低≥5 cm H2O的患者,样本量需求可减少超过50%而不增加筛查总人数。作者讨论了该框架对试验设计的潜在意义。
要点
- ECCO2R用于ARDS超保护性通气,可降低潮气量和驱动压这两个呼吸机相关肺损伤的关键决定因素。
- 死腔和静态顺应性决定ECCO2R对驱动压和机械功率的影响,该生理学框架可能预测个体对ECCO2R的治疗反应。
- 按预测治疗反应富集入组(预测性富集)比按基线死亡风险限制入组更能提高治疗效应量和统计效能。
- 模拟计算提示,仅纳入ECCO2R可使驱动压降低≥5 cm H2O的ARDS患者,样本量需求可减少超过50%而不增加筛查总人数。
适用人群与场景
- 急性呼吸窘迫综合征(ARDS)患者,接受超保护性通气并考虑使用体外二氧化碳清除(ECCO2R)。
- 模拟分析基于既有的ARDS患者队列。
诊断标准与关键阈值
- 预测性富集标准:ECCO2R允许驱动压降低≥5 cm H2O的患者被纳入试验。
处置流程与药物剂量
- 基于基础生理学概念,死腔和静态顺应性决定ECCO2R对驱动压和机械功率的影响,该框架可能用于预测个体对ECCO2R的治疗反应。
- 在试验设计中,按预测治疗反应选择性入组患者(预测性富集),而非按基线死亡风险限制入组。
研究设计与关键结果
- 本文为视角文章,应用精准医学范式于ECCO2R用于ARDS超保护性通气,用基础生理学概念展示死腔和静态顺应性决定ECCO2R对驱动压和机械功率的影响。
- 在既有ARDS患者队列中模拟ECCO2R对驱动压和死亡率的预测效应,计算提示仅纳入ECCO2R可使驱动压降低≥5 cm H2O的患者,样本量需求可减少超过50%而不增加筛查总人数。
证据类型、等级与局限
- 证据类型:视角文章,基于生理学概念和既有队列的模拟计算。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,按预测治疗反应(ECCO2R使驱动压降低≥5 cm H2O)富集入组,可能提高ARDS临床试验的治疗效应量和统计效能,并减少样本量需求而不增加筛查总人数。
- 该生理学框架可能用于预测个体对ECCO2R的治疗反应,并讨论了对试验设计的潜在意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In clinical trials of therapies for acute respiratory distress syndrome (ARDS), the average treatment effect in the study population may be attenuated because individual patient responses vary widely. This inflates sample size requirements and increases the cost and difficulty of conducting successful clinical trials. One solution is to enrich the study population with patients most likely to benefit, based on predicted patient response to treatment (predictive enrichment). In this perspective, we apply the precision medicine paradigm to the emerging use of extracorporeal CO2 removal (ECCO2R) for ultraprotective ventilation in ARDS. ECCO2R enables reductions in tidal volume and driving pressure, key determinants of ventilator-induced lung injury. Using basic physiological concepts, we demonstrate that dead space and static compliance determine the effect of ECCO2R on driving pressure and mechanical power. This framework might enable prediction of individual treatment responses to ECCO2R. Enriching clinical trials by selectively enrolling patients with a significant predicted treatment response can increase treatment effect size and statistical power more efficiently than conventional enrichment strategies that restrict enrollment according to the baseline risk of death. To support this claim, we simulated the predicted effect of ECCO2R on driving pressure and mortality in a preexisting cohort of patients with ARDS. Our computations suggest that restricting enrollment to patients in whom ECCO2R allows driving pressure to be decreased by 5 cm H2O or more can reduce sample size requirement by more than 50% without increasing the total number of patients to be screened. We discuss potential implications for trial design based on this framework.
参考来源
- Goligher EC, Amato MBP, Slutsky AS, et al. Applying Precision Medicine to Trial Design Using Physiology. Extracorporeal CO2 Removal for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017. PMID: 28636403. doi:10.1164/rccm.201701-0248CP
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。